Xenetic Biosciences Inc (NASDAQ:XBIO) Short Interest Update

Xenetic Biosciences Inc (NASDAQ:XBIO) saw a large drop in short interest in the month of February. As of February 15th, there was short interest totalling 6,500 shares, a drop of 15.6% from the January 31st total of 7,700 shares. Currently, 0.5% of the shares of the company are short sold. Based on an average trading volume of 12,400 shares, the days-to-cover ratio is currently 0.5 days.

Xenetic Biosciences Price Performance

XBIO opened at $3.83 on Thursday. The business has a 50 day simple moving average of $4.11 and a 200-day simple moving average of $4.03. The stock has a market capitalization of $5.91 million, a P/E ratio of -1.44 and a beta of 2.17. Xenetic Biosciences has a 12 month low of $2.78 and a 12 month high of $5.20.

Institutional Trading of Xenetic Biosciences

A hedge fund recently bought a new stake in Xenetic Biosciences stock. LGT Group Foundation purchased a new stake in Xenetic Biosciences Inc (NASDAQ:XBIO) in the 4th quarter, according to its most recent Form 13F filing with the SEC. The firm purchased 11,000 shares of the company’s stock, valued at approximately $41,000. LGT Group Foundation owned 0.71% of Xenetic Biosciences at the end of the most recent reporting period. Institutional investors and hedge funds own 15.12% of the company’s stock.

Analysts Set New Price Targets

Separately, HC Wainwright reissued a “neutral” rating on shares of Xenetic Biosciences in a report on Thursday, December 5th.

About Xenetic Biosciences

Xenetic Biosciences, Inc is a biopharmaceutical company focused on progressing XCART, a personalized CAR T platform technology engineered to target patient-specific tumor neoantigens. The Company is initially advancing cell-based therapeutics targeting the unique B-cell receptor on the surface of an individual patient’s malignant tumor cells for the treatment of B-cell lymphomas.